VEXAS syndrome

The American College of Rheumatology guidance statement on VEXAS syndrome

Published in March 2026, it sets out what an international panel considers established about the diagnosis, treatment and monitoring of a disease first described in 2020, and what is not.

First author · Arthritis & Rheumatology, March 2026 · DOI 10.1002/art.43287 · Read the page

At a glance
PositionProfessor of internal medicine and clinical immunology, hospital practitioner (PU-PH)
WhereSorbonne Université and Saint-Antoine Hospital (AP-HP), Paris; Saint-Antoine Research Centre, Inserm UMR_S 938
AreasVEXAS syndrome, autoinflammatory diseases and inflammatory amyloidosis, systemic autoimmune diseases, reproductive immunology, inflammatory manifestations of myeloid malignancies
Cited workFirst author of the American College of Rheumatology guidance statement on VEXAS syndrome (Arthritis & Rheumatology, March 2026, DOI 10.1002/art.43287)
NetworksCo-founder and coordinator of FRENVEX, the French VEXAS study group (2020); founder and chair of the MINHEMON network (2016); head of the CeRéMAIA constitutive site at Saint-Antoine Hospital, acquired inflammatory disorders including VEXAS syndrome
TeachingDirector of the university diploma in reproductive immunology, Sorbonne Université (since 2024)
CommitmentFounder and chair of the Santé Arménie association (2020)
IdentifiersORCID 0000-0003-2849-3049 · Scopus 23973320800 · IdRef 131898493
News
The first long-form pages will appear here.
Each will deal with one precise subject, with its sources and with what is not yet known.

See the section · What these writings are